Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer

Authors: U Lehmann, P Ahrens, LU Wingen, B Schlegelberger, F Länger, H Kreipe

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Promoter hypermethylation is a common inactivation mechanism in the development and progression of neoplastic transformation. For mammary carcinoma numerous genes have been described to be silenced due to aberrant methylation, some of them already in intraductal carcinomas. Much less is known about the association of hypermethylation events with the different histological subtypes of breast cancer. …
Metadata
Title
Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer
Authors
U Lehmann
P Ahrens
LU Wingen
B Schlegelberger
F Länger
H Kreipe
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1146

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Poster Presentation

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy

Oral Presentation

DNA damage response pathways in cancer causation and treatment

Poster Presentation

DNA copy number changes in breast cancer samples using array-CGH profiling

Poster Presentation

Alpha-1 antitrypsin genotypes in breast cancer patients

Oral Presentation

Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference

Poster Presentation

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits